Pyc Therapeutics
Clinical trials sponsored by Pyc Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Scientists track vision loss in rare genetic eye disease to pave way for future treatments Results expected Sep 2026 (estimated)
-
New eye injection aims to slow genetic blindness
Disease control OngoingThis study tests a new medicine called PYC-001, given as an injection into the eye, for people with a genetic condition that damages the optic nerve (OPA1 optic atrophy). The main goal is to check if the treatment is safe and tolerable. About 18 adults will receive a single dose,…
Phase 1 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental eye drug shows promise for rare Blindness-Causing disease
Disease control OngoingThis study tests an experimental drug called VP-001 for people with a rare genetic eye disease that causes vision loss. The drug is injected into the eye and aims to slow or stop further damage. Researchers will check safety and measure any changes in eyesight over about two year…
Phase 1/2 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Scientists track vision loss in rare genetic eye disease to pave way for future treatments
Knowledge-focused OngoingThis study follows 50 people with a rare inherited eye condition called PRPF31-related retinal dystrophy (RP11) to see how their vision changes over time. Researchers will measure things like visual acuity, retinal thickness, and quality of life using eye exams and questionnaires…
Sponsor: PYC Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC